Show simple item record

dc.contributor.authorRussell, N
dc.contributor.authorBurnett, A
dc.contributor.authorHills, R
dc.contributor.authorBetteridge, S
dc.contributor.authorDennis, Michael
dc.contributor.authorJovanovic, J
dc.contributor.authorDillon, R
dc.contributor.authorGrimwade, D
dc.date.accessioned2018-09-30T15:39:29Z
dc.date.available2018-09-30T15:39:29Z
dc.date.issued2018-08-10
dc.identifier.citationAttenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. 2018, Blooden
dc.identifier.issn1528-0020
dc.identifier.pmid30097508
dc.identifier.doi10.1182/blood-2018-05-851824
dc.identifier.urihttp://hdl.handle.net/10541/621266
dc.language.isoenen
dc.rightsArchived with thanks to Blooden
dc.titleAttenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.en
dc.typeArticleen
dc.contributor.departmentCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdomen
dc.identifier.journalBlooden


This item appears in the following Collection(s)

Show simple item record